Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas

Acta Neuropathol. 2023 Apr;145(4):497-500. doi: 10.1007/s00401-023-02544-6. Epub 2023 Feb 1.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cyclin-Dependent Kinase Inhibitor p16 / genetics
  • Genes, p16
  • Homozygote
  • Humans
  • Meningeal Neoplasms* / genetics
  • Meningioma* / genetics
  • Sequence Deletion

Substances

  • Cyclin-Dependent Kinase Inhibitor p16
  • CDKN2A protein, human